Abstract

Sesbania grandiflora (L.) Pers. is a valuable medicinal herb with numerous traditional uses, yet its contribution to an evidence-based therapeutic potential is incomplete. This comprehensive review focuses on the current state of knowledge, the mechanistic analysis of its activities, pharmacokinetics, pharmacodynamics, and clinical validation. It also reveals a rich phytochemical profile of compounds such as isoflavonoids (medicarpin), triterpenes (betulinic acid), and unique 2-arylbenzofurans with significant anti-tubercular activity. Mechanistic studies validate its anticancer activity modulating PI3K/Akt signalling pathways and the induction of mitochondrial-mediated apoptosis. Its apoptotic activity is linked to the inhibition of key carbohydrate-metabolizing enzymes. However, clinical translation is impeded by significant challenges, including the poor bioavailability of key lipophilic compounds, genotoxicity, and safety concerns. Still, robust clinical trial evidence provided that the first randomized controlled trial evaluated a standardized extract in improving heart health. In conclusion, while S. grandiflora confirms the confirmatory potential, its future as a modern botanical medicine depends on systematically managing the identified gaps in pharmacokinetics and long-term safety to develop standardized and efficacious formulations.

Key words: Sesbania grandiflora, Phytochemistry, Molecular Pharmacology, Anti-cancer, Anti-diabetic